DR. DEMETRIUS F LOUKAS M.D. NPI 1154369775

NPI Details

DR. Demetrius F Loukas, M.D. is a medical oncology internal medicine in Austin, TX with 55 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Demetrius F Loukas, M.D. NPI is 1154369775. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
Graduation Year:1971

The provider's business location address is:

901 W 38TH ST
SUITE 200
AUSTIN, TX
ZIP 78705-165
Phone: (512) 419-9733
Fax: (512) 451-3709

The NPI 1154369775 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Protein measurement, serum (HCPCS:84165)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Immunologic analysis technique on serum (HCPCS:86320)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Injection of drug or substance into vein (HCPCS:96374)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Unclassified drugs (HCPCS:J3490)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Uric acid level, blood (HCPCS:84550)
• Testosterone (hormone) level, total (HCPCS:84403)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Drawing of blood for a medical problem (HCPCS:99195)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)

The enumeration date for this NPI number is 6/4/2006 and was last updated on 3/3/2009.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.